Paloma Partners’s Integra LifeSciences IART Stock Holding History

Paloma Partners’s Portfolio IART Stock Details IART Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	–	Sell	-77,411	Closed	-$3.64M	–	2254
2020 Q2	$3.64M	Buy	77,411 +71,916	+1,309%	+$3.54M	0.06%	412
2020 Q1	$245K	Sell	5,495 -7,145	-57%	-$375K	0.01%	798
2019 Q4	$736K	Buy	+12,640	New	+$752K	0.01%	1142
2019 Q2	–	Sell	-45,153	Closed	-$2.52M	–	1944
2019 Q1	$2.52M	Buy	+45,153	New	+$2.3M	0.06%	362
2018 Q3	–	Sell	-186,486	Closed	-$12M	–	1711
2018 Q2	$12M	Buy	+186,486	New	+$11.5M	0.22%	75
2017 Q2	–	Sell	-17,681	Closed	-$745K	–	2295
2017 Q1	$745K	Buy	+17,681	New	+$755K	0.01%	1411
2016 Q4	–	Sell	-5,294	Closed	-$218K	–	2045
2016 Q3	$218K	Sell	5,294 -2,106	-28%	-$88.2K	﹤0.01%	1720
2016 Q2	$295K	Buy	+7,400	New	+$266K	﹤0.01%	1773
2015 Q3	–	Sell	-39,684	Closed	-$1.09M	–	1750
2015 Q2	$1.09M	Buy	+39,684	New	+$1.06M	0.02%	721

Other funds holding IART

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

CIP

Champlain Investment Partners Burlington, Vermont $7.88B AUM 6.82% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Cooke & Bieler Philadelphia, Pennsylvania $8.84B AUM 6.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

EVM

Eaton Vance Management Boston, Massachusetts $67.5B AUM 11.44% 1-Year Est. Return

Paloma Partners's IART Position: Q3 2020 in Review

Paloma Partners sold out of Integra LifeSciences (IART) in Q3 2020, closing a stake of 77,411 shares — an estimated $3.64M sold.

Paloma Partners first reported a position in IART in Q2 2015 and held it in 9 quarters. The position peaked at $12M in Q2 2018. 237 funds tracked by Wall St. Rank hold IART as of Q3 2020.

Paloma Partners reported no remaining Integra LifeSciences position as of Q3 2020 after selling out during the quarter.
Paloma Partners sold 77,411 Integra LifeSciences shares in Q3 2020, an estimated $3.64M.
Paloma Partners first reported a position in Integra LifeSciences in Q2 2015 and held it in 9 quarters.
Paloma Partners's Integra LifeSciences position peaked at $12M in Q2 2018.
237 funds tracked by Wall St. Rank held Integra LifeSciences as of Q3 2020.

Based on Paloma Partners's 13F filing for Q3 2020, filed 16 Nov 2020.